Skip to content
DataLookout
Menu

NCT07408609

Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Eligibility criteria expanded, about 2 words
    • Start date changed from estimate of Feb 26, 2026 to May 14, 2026
    • Secondary endpoints: details revised at 4 of 4 entries
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Pathological Complete Response (pCR) Rate (ITT Population)
Timeframe: At the time of surgery following completion of neoadjuvant therapy, based on pathological evaluation of the resected surgical specimen.

Secondary (4)

Pathological Complete Response (pCR) Rate (Surgical Population)
R0 Resection Rate
Event-Free Survival (EFS)
Overall Survival (OS)

Arms and interventions

Chemotherapy combined with TislelizumabExperimental
ChemotherapyActive comparator

Drugs: Low Dose Radiotherapy Combined with Tislelizumab and Chemotherapy, Chemotherapeutic Agent

Devices: low-dose radiotherapy

Sites

1 site in 1 country

  • Jiangsu Cancer Institute & HospitalNanjing, Jiangsu, China